Bonus BioGroup
Press Room

Sunday, 03 October 2021 04:21

Moshe Bar Siman Tov, former CEO of the Israeli Ministry of Health, joins the Business Advisory Board of Bonus BioGroup

Rate this item
(0 votes)

Moshe Bar Siman Tov,
former CEO of the Israeli Ministry of Health, joins the Business Advisory Board of Bonus BioGroup


Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products.

Bonus BioGroup is pleased to announce the addition of Moshe Bar Siman Tov, former CEO of the Israeli Ministry of Health, to the Company's Business Advisory Board, where he will serve together with Or Ben Shoshan, managing partner of the Southern Israel Bridging Fund ("SIBF"), an Israeli venture capital fund, and Malcolm I. Hoenlein, Executive Vice Chairman of the Conference of Presidents of Major American Jewish Organizations.

Moshe Bar Siman Tov said that "Advanced therapies changes and will continue to change the future of medicine in the world. Bonus BioGroup has achieved unique technological depth and innovation in the fields of cellular medicine and tissue engineering. In recent years, Bonus BioGroup has introduced unique and groundbreaking therapeutic solutions which are already changing the future of medicine, among them, the cellular drug product MesenCure intended for the rescue of severe COVID-19 patients from death, and a viable human bone implant for the repair of severe injuries to the skull and the limbs. Bonus BioGroup’s products may facilitate significant savings in healthcare costs, and therefore has huge potential to become a leading player in the global biotech arena. Naturally, the more innovative a development is, the more complex a strategy is required to realize its potential. I intend to assist the management of Bonus BioGroup in the international commercialization of its advanced therapies."

Dr. Shai Meretzki, CEO of Bonus BioGroup, stated that "We welcome the decision of Moshe Bar Siman Tov to join Bonus BioGroup, as part of the company's preparations to promote the implementation of its international strategy. Accordingly, the company reported[1] renting a building known as Building 20 in Matam park, in its entirety, of which about half of its area is intended for industrial-scale manufacturing activity of the company's products, and in the other half, the research and development activities of the company will be expanded."

Sincerely,

Bonus BioGroup

By: Yossi Rauch (Chairman of the Board) and Dr. Shai Meretzki (CEO and Director)

 

[1] Report dating August 29, 2021, reference 2021-01-139443

Read 202 times Last modified on Thursday, 28 October 2021 04:23

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.